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Background: We have previously shown that curcumin exhibited an outstanding anti-HCMV effect in vitro and
in vivo. However, the underlying mechanism for the anti-HCMV effect remains unclear.
Methods: Levels of IL-6 and TNF-α cytokine secretions in HELF cells were determined by enzyme-linked immunosorbent
assay (ELISA); cell cycles were assessed by flow cytometry; ie and ul83 gene expressions were evaluated using
reverse transcriptase real-time quantitative PCR; HCMV IE and UL83 antigen expressions were studied using
immunofluorescence staining assay and western blot.
Results: Curcumin reduced HCMV immediate early antigen (IEA) and UL83A expressions and IL-6, and TNF-α
secretions and recovered cell proliferation to normal level in HCMV infected HELF cells.
Conclusions: Curcumin anti-HCMV effect may possibly be that curcumin concurrently alters host cell microenviroment
and inhibits the HCMV antigen expressions. These findings may provide a basic understanding of the curcumin
anti-HCMV effect and a novel strategy for further development of curcumin anti-HCMV treatment.
Keywords: Human cytomegalovirus, Curcumin, Cytokine secretion, Cells cycle, Gene expression, Immediate early antigen,
IEA, UL83ABackground
Human Cytomegalovirus (HCMV) infects 50-90% of the
general adult population and has been implicated in
development of many diseases [1-3]. Although HCMV
infects a wide spectrum of cell types in vivo, most labora-
tory studies are carried out using fibroblasts because the
virus replicates relatively poorly in other cultured cells.
The course of HCMV infection in human fibroblasts
involves (i) direct fusion with the plasma membrane, (ii)
entry and delivery of capsids into the cytoplasm [4], (iii)
leaving viral DNA into the nucleus, and (iv) performing
gene expression. Lytic gene expression follows a regulated
cascade through three distinct phases: immediate-early
(IE), early (E), and late (L), and finally, to release infectious
virions. HCMV is known to highjack the host replication
machinery, alter the cell cycle, and manipulate the host
innate and adaptive immune responses [5]. IE72 and IE86,
the most abundant immediate-early antigens (IEA) of
HCMV, not only transactivate their own gene promoters* Correspondence: hongllh@126.com
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unless otherwise stated.and subsequent other viral gene promoters but also
regulate the host cell cycle related gene expressions by
interacting with cellular proteins to create a beneficial
cellular microenvironment for viral proliferation [6,7].
Early antigen (EA) is a series of enzymes, such as UL54
and regulatory factors that are necessary to synthesis of
progeny viral DNAs and proteins. Late antigens (LA)
are the virus structural proteins, among which include
UL83 and pp65 [8]. During the infection, HCMV enhances
expression of several cytokines, such as tumor necrosis
factor-alpha (TNF-α) and interleukin-6 (IL-6), for the viral
replication and dissemination [9], and inhibition and
blocking of normal cell cycle progression prior to S phase
to provide a favorable environment for viral replication
[10,11].Thus, HCMV may manipulate the host environ-
ment to establish productive infection and ensure progres-
sion of the viral replication cycle, which may cause serious
life threatening complications in immunocompromised
individuals.
Treatment of HCMV infections is difficult because there
are only a few options. To date, most of the licensed drugs
such as ganciclovir (GCV), valganciclovir, and cidofovirThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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drawbacks, including long-term toxicity, low potency, and
poor bioavailability. In addition, the emergence of drug-
resistant viral strains of HCMV has become an increasing
problem for the management of diseases caused by the
virus. Our previous work showed that curcumin, a hydro-
phobic polyphenol and a natural compound that is derived
from the rhizome of the herb Curcuma longa [13], exhib-
ited an outstanding anti-HCMV activity in vitro [14,15].
Due to a wide spectrum of biological and pharmacological
activities, curcumin is affirmed and promoted by bio-
logical medicine. Recently, it was found that curcumin
can effectively protect against the potentially fatal Rift
Valley fever (RVF) virus infection in vitro and in vivo
[16]. Currently, studies are in progress to evaluate the
activity of curcumin against the Bunyavirus, Venezuelan
equine encephalitis virus and retrovirus, including human
immunodeficiency virus (HIV). Therefore, curcumin may
be used as a broad-spectrum inhibitor to prevent a series
of virus infection in healthy cells.
However, there has been no study on the mechanism
of the curcumin anti-HCMV effect. The purpose of this
study was to investigate the mechanism of the curcumin
anti-HCMV effect. We found that curcumin had different
action mechanism than that of the polymerase targeting
anti-HCMV drugs. Curcumin likely prevented HCMV
from altering host cell microenviroment and HCMV




Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bo-
vine serum (FBS), SYBR Green, penicillin, streptomycin,
L-glutamine, trypsase, dimethlsulfoxide (DMSO), Triton
X-100, phenylmethanesulfonyl fluoride (PMSF), â-mer-
captoethanol (â-ME), TNF-α detection kit, IL-6 ELISA
kit, and cell cycle assay kit were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Mouse anti-HCMV IE
and mouse anti-HCMV UL83 were purchased from
Abcam, USA. Secondary antibody goat anti-mouse and
Platinum® Quantitative PCR SuperMix-UDG were obtained
from Invitrogen, USA. RNeasy Mini Kit and Sensiscript
Reverse Transcriptase Kit were purchased from Qiagen
(Valencia, CA, USA).
Cell culture and virus propagation
Human embryonic lung fibroblast (HELF) cells were pur-
chased from National Platform of Experimental Cell Re-
sources for Sci-Tech (Beijing, China) and cultured in
DMEM supplemented with 10% FBS, 100 U of penicillin/
ml, 100 ìg/ml of streptomycin, and 2 mML-glutamine at
37°C under a humidified condition of 95% air and 5%
CO2. HCMV laboratory strain AD169 was purchasedfrom ATCC, prepared in HELF cells and maintained in
DMEM with 2% FBS (maintenance medium). The max-
imal atoxic concentration (TC0) and half maximal inhibi-
tory concentration (IC50) of curcumin cytotoxicity and
GCV and viral titer were determined by plaque titration as
described previously [13,14].
Antiviral compounds
Curcumin was obtained from National Institute for Food
and Drug Control (Beijing, China) and stored as 50 mM
stock solution in DMSO for in vitro use. The high dose,
middle dose, and low dose of curcumin were 0.8, 0.4,
and 0.2 ìg/ml, respectively. The intravenous formulation
of GCV (Sigma-Aldrich, St. Louis, MO, USA) at 50 ìg/ml
in 0.9% saline was used as reference.
Enzyme-linked immunoabsorbent assay (ELISA)
HELF cells that were seeded at density of 1 × 106/ml in
tissue culture flasks were infected with HCMV at
100TCID50/0.1 ml. After incubation at 37°C for 2 h
under a humidified condition of 95% air and 5% CO2,
the supernatant was removed and replaced by the
maintenance medium with or without curicumin. After
48 hours, the supernatants were harvested and the
levels of inflammatory cytokines IL-6 and TNF-α were
detected.
Flow cytometry
HELF cells that were seeded at density 1 × 106/ml in tissue
culture flasks were synchronously cultivated for 12 h, and
then infected with HCMV at 100TCID50/0.1 ml. After
incubation at 37°C for 2 h under a humidified condition
of 95% air and 5% CO2, the supernatant was removed and
replaced by the maintenance medium with or without
curcumin. After 48 h, the cells were harvested, centri-
fuged at 800 g for 5 min, washed with cold PBS two
times, centrifuged at 800 g for 5 min, and re-suspended
with 70% ethanol at 4°C overnight. The cells were cen-
trifuged at 800 g for 5 min, washed with PBS three times
and incubated with 500 ìl of PBS containing 50 ìg/ml
propidium iodide (PI), 100 ìg/ml RNase A and 0.2% Triton
X-100 at 4°Cin a dark cabinetfor 30 min.
SYBR green reverse transcriptase real-time quantitative PCR
Total RNAs were extracted from cells and treated with
Dnaseusing a QiagenRNeasy kit according to the man-
ufacturer’s instructions. RNA (500 ng) was subjected
to reverse transcription. Each reaction mixture con-
tained a cDNA template, 10 μM of forward primer and
reverse primer [17,18] (Oligonucleotide primers (Beijing
DingguoChangsheng Biotechnology CO., Ltd, Beijing,
China) are as follows: IE forward 5′-AGACACCCGTG
ACCAAG-3′, IE reverse 5′-TCTGTTTGACGAGTTCTG
C-3′; UL83 forward 5′-ATGGTGGCTACGGTTCA -3′,
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forward 5′-AGACACCCGT GACCAAG-3′, GAPDH
reverse 5′-TTTGAGGGTGCAGCGAACTT-3′), 2 ×Mix,
10 × Sybr Green I and dH2O. Amplification was performed
by a cycle of initial denaturation at 94°C for 2 min; 40 cycle
of denaturation at 94°C for 30 s, annealing at 61°C for 30 s,
and elongation at 72°C for 30 s. The fluorescence threshold
value was calculated using ABI 7700 device system software
(Applied Biosystems Inc., Foster City, CA, USA). The
calculation of relative change in mRNA was performed
using the delta-delta method [19], with normalization to
GAPDH.
Immunofluorescence assay
Cells that were seeded on non-coated glass coverslips at a
density of 1 × 106/ml were washed with PBS three times
and fixed with 4% paraformaldehyde at room temperature
(RT) for 15 min. Cells were washed with PBS three times,
each time 5 min, followed by permeablization in 0.5%
Triton X-100/PBS for 8 min. The cells were washed
with PBS and blocked in blocking buffer (10% goat
serum in PBS) at 37°C for 1 h. After blocking, the cells
were incubated with primary mouse monoclonal anti-
human IE and UL83 antibodies in a moist chamber at
37°C for 1 h. Then the cells were rinsed with PBS and
incubated with secondary goat anti-mouse fluorescein-
conjugated antibody at 37°C for 1 h in a dark cabinet,
followed by successive washes with PBS and imaged at
200× using an Olympus microscope (Olympus IX71,
Japan). The acquired images were processed using Adobe
Photoshop software.
Western blotting
The cells were washed with cold PBS twice and lysed in
an appropriate volume of cold RIPA buffer [25 mM
Tris–HCl pH 7.6, 150 mM NaCL, 1% NP-40, 1% sodium
deoxycholate, 1 mM PMSF and 0.1% sodium-dodecyl
sulphate (SDS)] on ice for 30 min; then they were
crushed at 4°C and centrifuged at 9600 g for 10 min.
The supernatant was removed and denatured by heating
at 95°C for 10 min. Proteins were separated by SDS-PAGEFigure 1 Effect of curcumin on IL-6 and TNF-α secretions in HCMV inf
(model); C, HELF cells + HCMV + GCV; D, HELF cells + HCMV + curcumin (hig
0.4 ìg/ml); F, HELF cells + HCMV + curcumin (low dose: 0.2 ìg/ml).**P < 0.01
with HCMV infection.(Mini-Protean®Tetra System, Bio-RAD, Hercules, CA,
USA), electroblotted onto nitrocellulose membranes
(Mini-Trans-Blot, Bio-RAD, Hercules, CA, USA). After
being blocked with 5% skim milk in Tris-buffered saline
(TBS) consisting of 100 mmol/L Tris · HCL, 150 mmol/L
NaCL, pH 7.4 at room temperature for 2 h, the blots were
incubated with primary antibodies at the recommended
dilutions at 4°C overnight, followed by washing with
0.05% Tween-20 in TBS (TBST) three times. Then the
blots were then incubated with Alexa Fluor®680 goat anti-
mouse IgG and goat anti-rabbit IgG at 1:10000 (Invitro-
gen, Grand Island, NY, USA) in TBST. After washing the
membranes with TBS, signals were detected using Odyssey
infrared laser imaging system (Li-COR, American) accord-
ing to the manufacturer’s instructions. For densitometric
analysis of western blot images, density profiles of the
bands were measured using ImageJ software.Statistical analysis
Data were analyzed using Microsoft Office Excel 2003
and expressed as mean ± standard error (SE). Group
comparisons were evaluated using the one-way ANOVA,
and significant differences between treatments were
determined using the post hoc test with Tukey-Kramer
HSD simultaneous pair wise main comparison. P values
less than 0.05 were considered to be statistically
significant.Results
Effect of curcumin on HCMV-induced cytokine secretion
in HELF cells
After incubation of HELF cells with HCMV for 48 h, the
concentrations of IL-6 and TNF-α in model cells (cells
only infected with HCMV) were 431.46 ± 21.3 (Figure 1A)
and 13.67 ± 1.02 pg/mL (Figure 1B), respectively, which
were markedly increased compared to the control
(Figure 1A; P < 0.01). In contrast, the concentrations
of IL-6 and TNF- α in curcumin treated groups were
slightly higher than basal levels, and significantly different
from model cells (Figure 1D-F; P < 0.05).ected HELF cells. A, HELF cells (control); B, HELF cells + HCMV
h dose: 0.8 μg/ml); E, HELF cells + HCMV + curcumin (Middle dose:
, *P < 0.05 compared with the control; ##P < 0.01, #P < 0.05 compared
Figure 3 Effect of curcumin on HCMV IE and UL83 expressions.
(I) Relative HCMV IE mRNA expression was normalized to GAPDH
mRNA levels and expressed as fold change. (II) Relative HCMV UL83
mRNA expression was normalized to GAPDH mRNA levels and
expressed as fold change. A, HELF cells (control); B, HELF cells + HCMV
(model); C, HELF cells + HCMV+GCV; D, HELF cells + HCMV+ curcumin
(high dose: 0.8 μg/ml); E, HELF cells + HCMV+ curcumin (middle dose:
0.4 μg/ml); F, HELF cells + HCMV + curcumin (low dose: 0.2 μg/ml).
**P < 0.01, *P < 0.05 compared with the control; ##P < 0.01, #P < 0.05
compared with HCMV infection.
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The effect of curcumin on the HELF cell cycle infected
by HCMV was investigated using flow cytometry. After
incubation of HELF cells with HCMV for 48 h, the S
phase fraction in model cells (Figure 2B) was significantly
greater than in the control cells (Figure 2A; P < 0.05),
while G0/G1 and G2/M phase fraction in model cells were
less than in the control cells (Figure 2A-B; P < 0.05),
which indicated that HCMV inhibited cell proliferation.
Compared to model cells, cell proliferation of curcumin
treated groups (Figure 2D-F) basically returned to normal
levels (Figure 2D-F; P < 0.05).
Down-regulation of the gene expression of HCMV ie and
ul83 by curcumin
To further explore the mode of action of curcumin, we
evaluated the effect of curcumin on HCMV IE and
UL83 mRNA expressions using real-time quantitative
PCR (Figure 3). At the indicated time points (48 h post
infection), there were no HCMV IE or UL83 mRNA ex-
pression (Figure 3A) in mock cells. In contrast, there were
significant HCMV IE and UL83 mRNA expressions
(Figure 3B) found in cells infected by HCMV (P < 0.01).
A distinct reduction of IE and UL83 mRNA expressions-
were observed in cells treated with curcumin (Figure 3D-F;
P < 0.01).
Modulation of HCMV IE antigen (IEA) and UL83 antigen
(UL83A) levels by curcumin
We next determined if the transcriptional changes by
curcumin also affected HCMV IEA and UL83A levels in
the cells at 48 h post infection. HCMV infection increased
the levels of IEA and UL83A expressions (Figures 4B
and 5B) compared to the mock-infected cells (Figures 4A
and 5A; P < 0.01). However, HCMV IEA and UL83A
expressions were obviously down-regulated in the cells
treated with curcumin (Figure 4D-F and 5D-F; P < 0.05).
Discussion
To address the mechanism of curcumin in the anti-HCMV
effect, we investigated the proliferation, HCMV IEA andFigure 2 Effect of curcumin on HCMV infected HELF cell cycle. A, HELF c
D, HELF cells + HCMV+ curcumin (high dose: 0.8 μg/ml); E, HELF cells + HCMV
(low dose: 0.2 μg/ml). *P < 0.05 compared with the control; #P < 0.05 comparUL83A expressions, IL-6 and TNF-α secretions and ieand
ul83 gene expressions of HELF cells treated by curcumin
using flow cytometry, western blotting/immunofluores-
cence assay, ELISA and RT qPCR, respectively. We
identified that curcumin concurrently altered the host
cells microenviroment and inhibited the HCMV antigen
expressions in HCMV infected HELF cells. We found
that IL-6 and TNF-α levels in the cells infected with
HCMV were significantly higher than in the mock infected
cells, but curcumin significantly reduced the secretion
of the two cytokines, suggesting that curcumin may be
an effective anti-HCMV infection agent. TNF-α may
promote HCMV replication that may in turn increase
the TNF-α secretion level. In fact, IL-6 and TNF-α
levels in HCMV infected patients’sera are significantly
higher, and the high level of IL-6 may indicate a higher
risk of HCMV infection, thus being beneficial for early
diagnose of HCMV infection [20,21].ells (control); B, HELF cells + HCMV (model); C, HELF cells + HCMV+ GCV;
+ curcumin (middle dose: 0.4 μg/ml); F, HELF cells + HCMV + curcumin
ed with HCMV infection.
Figure 4 Effect of curcumin on HCMV IE and UL83 protein expressions (200X). A, HELF cells (control); B, HELF cells + HCMV (model); C, HELF
cells + HCMV + GCV; D, HELF cells + HCMV + curcumin (high dose: 0.8 μg/ml); E, HELF cells + HCMV + curcumin (middle dose: 0.4 μg/ml); F, HELF
cells + HCMV + curcumin (low dose: 0.2 μg/ml).
Lv et al. BMC Complementary and Alternative Medicine 2014, 14:284 Page 5 of 7
http://www.biomedcentral.com/1472-6882/14/284We found that the percentages of S phase of the HCMV
infected cells were significantly higher, but the percentages
of G0/G1 and G2/M phases were much lower in the
HCMV infected cells than in the mock infected cells. The
cell cycle of HCMV infected cells basically recovered to
normal status after curcumin treatment. These results
indicated that curcumin may improve the cell cycle of
HCMV infected cells which in turn may further inhibit
the proliferation and replication of the virus. It was found
that after HCMV infection in S phase, the host cells cycle
progress was stopped in S phase, followed by cell patho-
logic mitosis [22], and that HCMV infected cells stoppedFigure 5 Effect of curcumin on HCMV IE and UL83 antigen expression
protein levels were normalized to β-actin protein levels and expressed as p
Relative HCMV UL83A protein levels were normalized to β-actin protein lev
(model); C, HELF cells + HCMV + GCV; D, HELF cells + HCMV + curcumin (hig
0.4 μg/ml); F, HELF cells + HCMV + curcumin (low dose: 0.2 μg/ml).**P < 0.0
HCMV infection.dividing after entering the S phase [23]. It’s worth noting
that the cell cycle changes caused by HCMV were related
to alterations of cell cycle factors, including increasing of
CyclinE transcription activity, activating cyclin-dependent
kinases (Cdks) and reducing the abundance of Cdk inhibi-
tors (CKIs) [11,24,25]. Therefore, whether curcumin alters
these cell cycle factors to regulate the cells cycle of HCMV
infected cells needs to be further investigated.
Our previous work showed that curcumin likely down-
regulated the expressions of HCMV IE and UL83 mRNAs
by semi-quantitative PCR (data not shown), thereby we
further studied the molecular mechanism of curcumin ins. (I) HCMV IEA expression by Western blot. (II) Relative HCMV IEA
ercentage (%). (III) HCMV UL83A expression by Western blot. (IV)
els and expressed as%. A, HELF cells (control); B, HELF cells + HCMV
h dose: 0.8 μg/ml); E, HELF cells + HCMV + curcumin (middle dose:
1 compared with the control; ##P < 0.01, #P < 0.05 compared with
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that curcumin significantly reduced HCMV IE and
UL83 mRNA expressions and IEA and UL83 protein
expressions. These findings suggest that the curcumin
anti-HCMV effect may be through the inhibition of
antigen IEA and UL83A expressions, which is different
from the GCV anti-HCMV mechanism targeting viral
DNA polymerase UL54 [12]. HCMV infection provokes a
proinflammatory response characterized by an increased
expression of chemokines, adhesion molecules, and modu-
lation of angiogenesis, which in turn promotes progressive
HCMV infection. IL-6 drives reactivation of latent HCMV
infection by transcriptional upregulation of IE genes [26];
HCMV IE and late proteins play important roles in im-
mune evasion such as TNF-mediated death receptor
signaling pathway, TNF-α release, IL-6 production [27,28].
We deduce that curcuminreduces HCMV IE and UL83
expression, which in turn decreases inflammatory factor
secretion and recovers host cell cycle to normal status. In
fact, viral IE and UL83 expression play a key role in the
pathogenesis of HCMV infection [29,30]. Yet a further
study of the curcumin anti-HCMV infection mechanism
is necessary.
Conclusion
We have identified that curcumin had a clear anti-HCMV
effect and suggest that the underlying mechanism may be
that curcumin alters the host cells microenviroment and
inhibits the of HCMV protein expressions. These findings
may present curcumin as a novel drug in anti-HCMV
treatment with different mechanism of action from the
existing polymerase targeting anti-HCMV drugs.
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